The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey
Therapeutic Advances in Respiratory Disease · 2024-01 · 18
DOI: 10.1177/17534666231218886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 15.02.2024. Verfasst von Mark Small und 3 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Franchise, Adelphi Real World, Adelphi Mill, Grimshaw Ln, Bollington, Macclesfield, SK10 5JB, UK. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Pulmonary arterial hypertension (PAH) is a life-threatening, progressive disease often diagnosed late in its course.
Objectives
To present patient-reported data that were captured within a large, multinational, point-in-time survey of PAH-treating physicians and their patients to better understand the diagnostic journey.
Design
Cross-sectional survey conducted in five European countries (EU5), Japan and the USA.
Methods
PAH-treating pulmonologists, cardiologists, rheumatologists or internists (USA only) completed a patient record form (PRF) for the next four consecutive adult PAH patients they saw; these patients filled in a patient self-completion (PSC) form on an anonymous, voluntary basis. Our report focuses on patient data; data are from PSC forms unless stated otherwise.
Results
Physician-reported PRFs and self-completed PSC forms were obtained for 1152 and 572 patients, respectively. Patients’ mean (SD) age was 59.1 (14.0) years, 55.6% were female, and 57.3% had idiopathic PAH. Patient-reported data showed an average delay of 17.0 months between symptom onset and PAH diagnosis. This is longer than physicians estimated (13.8 months): this disparity may be partly due to the time taken by patients to consult a physician about their symptoms [9.6 months overall, longest in the USA (15.3 months)]. Most patients (71.6%) initially consulted primary care physicians about their symptoms and 76.4% of patients were referred to a specialist. Misdiagnoses occurred in 40.9% of patients [most frequent in the USA (51.3%), least common in Japan (27.6%)] and they saw an average of 2.9 physicians overall (3.5 in EU5 versus 2.0 in Japan/USA) before being diagnosed. Diagnosis was most often made by cardiologists (50.4%) or pulmonologists (49.3%).
Conclusion
Our data suggest that diagnostic delay in PAH results from patient- and physician-related factors, which differ across regions and include lack of awareness of PAH on both sides. Development of better screening strategies may help address this barrier to timely PAH diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Franchise, Adelphi Real World, Adelphi Mill, Grimshaw Ln, Bollington, Macclesfield, SK10 5JB, UK.
- Medical Affairs, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Allschwil, Switzerland.
- Respiratory Franchise, Adelphi Real World, Bollington, UK.
- Market Access, Janssen-Cilag GmbH, Neuss, Germany.
ORCID-Profile: Mark Small
Zitieren
APA
Small, M., Perchenet, L., Bennett, A., & Linder, J. (2024). The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666231218886
Vancouver
Small M, Perchenet L, Bennett A, Linder J. The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey. Therapeutic Advances in Respiratory Disease. 2024;18. doi:10.1177/17534666231218886
BibTeX
@article{Small2024,
author = {Small, Mark and Perchenet, Loïc and Bennett, Alex and Linder, Jörg},
title = {The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2024},
volume = {18},
doi = {10.1177/17534666231218886}
}
EUVIMED